Welcome to Nordic Bioscience

Nordic Bioscience discovers and develops innovative medical treatments to help millions of people around the world suffering from serious, chronic, degenerative diseases such as osteoporosis and osteoarthritis.

Since its incorporation in 1989, Nordic Bioscience has strived to revolutionize in vitro diagnostics enabling the Company to discover and design innovative drug development programme.

The Company has launched state-of-the art immunodiagnostic tests such as CTX-I and CTX-II for quantitative assessment of bone and cartilage loss, respectively, and currently Nordic Bioscience has more than 30 novel biomarkers in late stage development.

Located in Copenhagen and Beijing, and with a dedicated and experienced scientific team, Nordic Bioscience is positioned to take a leading role in the fight against osteoporosis, osteoarthritis, cardiovascular diseases, diabetes and other serious illnesses.